TempraMed Featured on Dr. Phil Show in National US Broadcast Highlighting the Risk of Temperature Exposure for Insulin and Other Medications
Vancouver, British Columbia--(Newsfile Corp. - May 22, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed a medical technology innovator transforming how temperature sensitive medications are stored and managed, is pleased to announce that TempraMed is featured on the Dr. Phil Show in a national broadcast episode focused o
Technology, Biotechnology, Pharmaceuticals, Health
2026-05-22 11:57 AM EDT | TempraMed Technologies Ltd.
Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today closed its previously announced underwritten public offering (the "Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company issued 2,400,000 common s
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-21 1:07 PM EDT | Optimi Health Corp.
TMC Group Commissions New Capacity to Support Next-Generation Radiotheranostics
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - As demand for radiotheranostics continues to grow exponentially, TMC Group, a Canadian manufacturer of high-purity enriched stable isotopes, is commissioning new production lines this year. This will add 50 percent more capacity to help ensure reliable supply for radiopharmaceutical research, clinical development, and future commercialization. TMC Group will be exhibiting at the 2026 Society of Nuclear Medicine and Molecular
Technology, Biotechnology, Chemical, Pharmaceuticals
2026-05-21 10:00 AM EDT | TMC Group
Britannia Life Sciences Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - May 21, 2026) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") today provides a corporate update on its current asset position, strategic direction, and capital markets initiatives. The Board of Directors has approved a refined corporate strategy which repositions Britannia as a public market "venture builder and company accelerator." Separately, the Board has also approved the commencement of a normal course issuer bid (the "NCIB")
Biotechnology, Household / Consumer / Cosmetics, Health, Cannabis Ancillary Service Provider
2026-05-21 9:08 AM EDT | Britannia Life Sciences Inc
Restart Life Sciences Closes Dedicated Purchase Order Financing Private Placement; CEO Subscribes for 50% of Offering
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that it has successfully closed its previously announced non-brokered private placement offering (the "Offering") of units (the "Units") to establish a revolving purchase order ("PO") financing source for its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"). The Company has issued a total
Technology, Biotechnology, Health
2026-05-21 6:00 AM EDT | Restart Life Sciences Corp.
Theralase(R) Closes C$4.8 Million Offering
Toronto, Ontario--(Newsfile Corp. - May 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has closed its previously announced brokered private placement offering ("Brokered Offering
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-05-20 11:06 AM EDT | Theralase Technologies Inc.
Envoy Medical Announces New Patents Expanding Intellectual Property Portfolio in Fully Implanted Hearing Technology
White Bear Lake, Minnesota--(Newsfile Corp. - May 20, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of multiple patents across Australia and Europe, as well as the upcoming grant of an additional European patent, further expanding the Company's intellectual property portfolio and reinforcing its position in the cochlear implant i
Biotechnology, Healthcare and Hospitals
2026-05-20 8:30 AM EDT | Envoy Medical, Inc.
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
Vancouver, British Columbia--(Newsfile Corp. - May 20, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced the pricing of its underwritten public offering (the " Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company is offering 2,400,000 common shares at a public o
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-20 8:00 AM EDT | Optimi Health Corp.
Optimi Health gibt Preisfestsetzung für überzeichnetes öffentliches Angebot in Höhe von 15 Mio. US-$ und Nasdaq-Uplisting bekannt
Vancouver, British Columbia--(Newsfile Corp. - Mittwoch, 20. Mai 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (das "Unternehmen" oder "Optimi"), ein pharmazeutisches Unternehmen im kommerziellen Stadium mit Fokus auf die Herstellung und den Vertrieb fertiger psychedelischer Arzneimittelprodukte, gab heute die Preisfestsetzung seines gezeichneten öffentlichen Angebots (das "Angebot") im Zusammenhang mit dem Uplisting seiner Stammaktien an den Nasdaq Capital Market bek
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-20 8:00 AM EDT | Optimi Health Corp.
Marvel Biosciences Announces Grant of Deferred Share Units
Calgary, Alberta--(Newsfile Corp. - May 20, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 50,001 deferred share units ("DSUs") to Marvel's three independent directors, in lieu of cash payment for directors' fees. The DSUs will all vest on May 19, 2027. Vested DSUs shall be settled upon the directors' separation from service from the Com
2026-05-20 7:00 AM EDT | Marvel Biosciences Corp.
PreveCeutical Announces Extension of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated May 12, 2026 and April 22, 2026, it has extended the closing of its private non-brokered private placement (the "Offering") of units of the Company (each, a "Unit") to raise gross proceeds of $1,000,000 to June 12, 2026 and intend
Biotechnology, Pharmaceuticals, Health
2026-05-19 7:36 PM EDT | PreveCeutical Medical Inc.
Resverlogix Closes US$2 Million Shares-for-Interest Private Placement
Calgary, Alberta--(Newsfile Corp. - May 19, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") announced today that it has closed a $2,760,057 (US$2,000,000) shares-for-interest private placement (the "Transaction") with an arm's length subscriber (the "Subscriber"). Under the terms of the Transaction, the Subscriber subscribed for 26,864,133 common shares at CAD$0.103 per share, equal to the applicable 5-day volume-weighted average price, for aggregate proceeds of CAD$2,760,057 (US
Technology, Biotechnology, Healthcare and Hospitals
2026-05-19 5:15 PM EDT | Resverlogix Corp.
Maxwell Biosciences' Claromers Destroy Epstein-Barr
Austin, Texas--(Newsfile Corp. - May 19, 2026) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired, broad spectrum small molecules called Claromers®, today announces Claromers destroy Epstein-Barr virus, according to a third-party lab study.
Biotechnology, Pharmaceuticals
2026-05-19 9:00 AM EDT | Maxwell Biosciences, Inc.
NorthPalm Capital Launches as AI-Augmented Investment Company
Toronto, Ontario--(Newsfile Corp. - May 19, 2026) - NorthPalm Capital Corp. (CSE: NP) ("NorthPalm" or the "Company") is pleased to announce the launch of NorthPalm Capital[1], an AI-augmented investment company focused on identifying and supporting high-growth opportunities across technology and digital asset sectors. The launch reflects NorthPalm's evolution into a leaner, high-conviction investment company with a modern approach to sourcing, evaluating, and act
Biotechnology, Healthcare and Hospitals, Health
2026-05-19 8:36 AM EDT | NorthPalm Capital Corp.
Neural Portfolio Company Hanf.com Expands German Retail Footprint with New Muhldorf am Inn Store and Four Refurbished Locations
Toronto, Ontario--(Newsfile Corp. - May 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers, is pleased to announce the opening of a new Hanf.
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-19 7:30 AM EDT | Neural Therapeutics Inc.
InMed Pharmaceuticals Amends Preferred Investment Options
Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into an amending agreement with Armistice Capital Master Fund Ltd. ("Armistice") in respect of certain outstanding preferred investment options held b
Biotechnology, Pharmaceuticals
2026-05-19 6:00 AM EDT | InMed Pharmaceuticals
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the expansion of internal capabilities to execute critical stages of its ACCUM®-enabled Antibody Drug Conjugates ("ADC") development pipeline. The Company has strengthened its purification, analytical characterization, conjugation
Biotechnology, Pharmaceuticals, Health
2026-05-19 3:15 AM EDT | Defence Therapeutics Inc.
Microbiome Labs launches EpicDefense on Amazon
Franklinton, North Carolina--(Newsfile Corp. - May 18, 2026) - Microbiome Labs™, a leader in microbiome-based solutions, announces the official launch of EpicDefense™ on Amazon, expanding consumer access to its latest microbiome-focused immune-support formula. EpicDefense is formulated to support the body's natural defenses and promote respiratory com
2026-05-18 10:00 AM EDT | Microbiome Labs
Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation
British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced the expansion of its collaboration with Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, broadening the scope of their
Biotechnology, Pharmaceuticals, Health
2026-05-18 7:00 AM EDT | BioHarvest Sciences Inc.
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
$5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 $4.5 million of accrued VAT refunds and R&D refundable tax credits from UK subsidiary begin maturing, including $1.9 million VAT cash refund expected in June 2026 Successful EMA and Australia TGA (ATGA) meetings aligned around use of existing biomarker and pending release of 3-year overall
2026-05-18 6:30 AM EDT | OS Therapies